Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Candida auris has simultaneously emerged on five continents as a fungal pathogen causing nosocomial outbreaks. The challenges in the treatment of C. auris infections are the variable antifungal susceptibility profiles among clinical isolates and the development of resistance to single or multiple classes of available antifungal drugs. Here, the in vitro susceptibility to echinocandin antifungal drugs was determined and FKS1 sequencing was performed on 106 C. auris clinical isolates. Four isolates were identified to be resistant to all tested echinocandins (MIC ≥ 4 mg/liter) and harbored an S639F mutation in FKS1 hot spot region 1. All remaining isolates were FKS1 wild type (WT) and echinocandin susceptible, with micafungin being the most potent echinocandin (MIC 50 = 0.125 mg/liter). Antifungal susceptibility testing with caspofungin was challenging due to the fact that all FKS1 WT isolates exhibited an Eagle effect (also known as the paradoxical growth effect), which occurred at various intensities. To assess whether the Eagle effect resulted in pharmacodynamic resistance, 8 representative isolates were evaluated for their in vivo drug response in a murine model of invasive candidiasis. All isolates were susceptible to caspofungin at a human therapeutic dose, except for those harboring the S639F mutation. The data suggest that only isolates carrying mutations in FKS1 are echinocandin resistant and that routine in vitro testing of C. auris isolates for susceptibility to caspofungin by the broth microdilution method should be viewed cautiously or avoided.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, isochromosome (5L), a specific aneuploidy in C. albicans, results in the formation of two extra copies of the left arm of chromosome 543, and, consequently, extra copies of TAC1 and ERG11, genes that confer resistance to azoles in these strains50.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [43]
In the citing paper
“Copy number variations, including whole-chromosome aneuploidy and shorter-range amplifications, are genome changes that can increase resistance32,43–49.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [43]
In the citing paper
“Importantly, limited ECN susceptibility was reported for all 3 isolates in a previous study (36), thus confirming the robustness of our phenotyping.”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [36]
In the citing paper
“Based on CDC-suggested breakpoints for ECNs (MICs of >4 μg/mL for AFG and MFG and >2 μg/mL for CSP [37]), these isolates can be considered ECN-R, as pointed out previously (36).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [36]
In the citing paper
“The clinical features of these infections include biofilm persistence on abiotic surfaces and skin, immune evasion, and antifungal drug resistance (7–12).”
From Dual function of Candida auris mannosyltransferase, MNT5, in biofilm community protection from antifungal therapy and the host (2025) · cites this paper as [9]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
How to calculate sample size in animal studies?
Charan, J., & Kantharia, N. D. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119726 · Cited by 1,881 · cited 1×
“The sample size of this animal experiment was considered adequate on the basis of the resource equation method (49).”
MethodLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 5×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundInfluentialSelf-citationSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
First hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768
Self-citationChowdhary, A., Sharma, C., & Meis, J. F. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006290 · Cited by 750
Self-citationChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577 · cited 2×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundSelf-citationKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 12×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundResultInfluentialSelf-citationFirst Three Reported Cases of Nosocomial Fungemia Caused by Candida auris
Lee, W. G., Shin, J. H., Uh, Y., Kang, M. G., Kim, S. H., Park, K. H., & Jang, H.-C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00319-11 · Cited by 523
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454
Calvo, B., Melo, A. S. A., Perozo-Mena, A., Hernandez, M., Francisco, E. C., Hagen, F., Meis, J. F., & Colombo, A. L. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.07.008 · Cited by 448
Research works printed but not linked: 2
- Public Health England. 2017. Guidance for the laboratory investigation, management and infection prevention and control for cases of Candida auris. Last updated 11 August 2017. Public Health England, London, United Kingdom.
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Candida auris: Epidemiology, biology, antifungal resistance, and virulence
Du, H., Bing, J., Hu, T., Ennis, C. L., Nobile, C. J., & Huang, G. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008921 · Cited by 609
“auris with an S639F mutation in Fks1 were caspofungin resistant, while other isolates harboring a wild-type Fks1 were susceptible to caspofungin at human therapeutic doses [74].”
BackgroundThe Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
Chow, N. A., Muñoz, J. F., Gade, L., Berkow, E., Li, X., Welsh, R. M., Forsberg, K., Lockhart, S. R., Adam, R., Alanio, A., et al. (2020) · doi:10.1101/2020.01.06.896548 · Cited by 463
Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris
Cortegiani, A., Misseri, G., Fasciana, T., Giammanco, A., Giarratano, A., & Chowdhary, A. (2018) · Journal of Intensive Care · doi:10.1186/s40560-018-0342-4 · Cited by 329
Self-citationMolecular mechanisms governing antifungal drug resistance
Lee, Y., Robbins, N., & Cowen, L. E. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00007-2 · Cited by 304
“Several amino acid substitutions in FKS1 have also been associated with decreased echinocandin susceptibility in C. auris 12,37 – 42 .”
Ahmad, S., & Alfouzan, W. (2021) · Microorganisms · doi:10.3390/microorganisms9040807 · Cited by 269
“auris to echinocandins, usually due to mutations in FKS1 gene [41,58,71,72,162].”
BackgroundReview on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris
Chaabane, F., Graf, A., Jequier, L., & Coste, A. T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02788 · Cited by 223
“The latter was confirmed to cause echinocandin resistance in vivo in a mouse model (Kordalewska et al., 2018).”
BackgroundKean, R., Delaney, C., Sherry, L., Borman, A., Johnson, E. M., Richardson, M. D., Rautemaa-Richardson, R., Williams, C., & Ramage, G. (2018) · mSphere · doi:10.1128/msphere.00334-18 · Cited by 220
“Hot spot mutations in ERG11 and FKS1 have been identified as resistance mechanisms in azole- and echinocandin-resistant strains, respectively (7, 8).”
BackgroundCarolus, H., Pierson, S., Muñoz, J. F., Subotić, A., Cruz, R. B., Cuomo, C. A., & Van Dijck, P. (2021) · mBio · doi:10.1128/mbio.03333-20 · Cited by 211
Candida auris and multidrug resistance: Defining the new normal
Lockhart, S. R. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103243 · Cited by 205
Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents
Jacobs, S. E., Jacobs, J. L., Dennis, E. K., Taimur, S., Rana, M., Patel, D., Gitman, M., Patel, G., Schaefer, S., Iyer, K., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00053-22 · Cited by 190
Combined Antifungal Resistance and Biofilm Tolerance: the Global Threat of Candida auris
Kean, R., & Ramage, G. (2019) · mSphere · doi:10.1128/msphere.00458-19 · Cited by 152
“Assessment of echinocandin sensitivity should be exercised with caution due to the paradoxical effect observed with caspofungin; instead, micafungin or anidulafungin should be used for testing (18).”
BackgroundCandida auris Genetics and Emergence
Chowdhary, A., Jain, K., & Chauhan, N. (2023) · Annual Review of Microbiology · doi:10.1146/annurev-micro-032521-015858 · Cited by 158
Self-citationThe Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145
Self-citationChakrabarti, A., & Sood, P. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001318 · Cited by 133
“The S639F mutation appears to confer pan-echinocandin resistance and S639 substitutions has been found associated with micafungin resistance in 90 % of echinocandin-resistant C. auris strains [26, 133, 135].”
Identification of Drug Resistant Candida auris
Kordalewska, M., & Perlin, D. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01918 · Cited by 124
“We reported a significant challenge with obtaining an accurate AFST MIC readout for caspofungin since all tested isolates exhibited an Eagle effect (also known as the paradoxical growth effect), with the intensities of the Eagle effect varying among the isolates (Kordalewska et al., 2018).”
InfluentialSelf-citationIbrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129
Emergence of Candida auris in Brazil in a COVID-19 Intensive Care Unit
de Almeida, J. N., Francisco, E. C., Hagen, F., Brandão, I. B., Pereira, F. M., Presta Dias, P. H., de Miranda Costa, M. M., de Souza Jordão, R. T., de Groot, T., & Colombo, A. L. (2021) · Journal of Fungi · doi:10.3390/jof7030220 · Cited by 120
“ERG11 and FKS1 mutations were also investigated by PCR [6,7] and amplicon Sanger DNA sequencing.”
MethodRybak, J. M., Cuomo, C. A., & David Rogers, P. (2022) · Current Opinion in Microbiology · doi:10.1016/j.mib.2022.102208 · Cited by 113
Kim, H. Y., Nguyen, T. A., Kidd, S. E., Chambers, J., Alastruey‐Izquierdo, A., Shin, J.-H., Dao, A., Forastiero, A., Wahyuningsih, R., Chakrabarti, A., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myae042 · Cited by 123
Resistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
Multi-omics Signature of Candida auris , an Emerging and Multidrug-Resistant Pathogen
Zamith-Miranda, D., Heyman, H. M., Cleare, L. G., Couvillion, S. P., Clair, G. C., Bredeweg, E. L., Gacser, A., Nimrichter, L., Nakayasu, E. S., & Nosanchuk, J. D. (2019) · mSystems · doi:10.1128/msystems.00257-19 · Cited by 99
Candida auris : multi-omics signature of an emerging and multidrug-resistant pathogen
Zamith-Miranda, D., Heyman, H. M., Cleare, L. G., Couvillion, S., Clair, G., Bredeweg, E., Gacser, A., Nimrichter, L., Nakayasu, E. S., & Nosanchuk, J. D. (2019) · doi:10.1101/528232 · Cited by 99
Ghannoum, M., Arendrup, M. C., Chaturvedi, V. P., Lockhart, S. R., McCormick, T. S., Chaturvedi, S., Berkow, E. L., Juneja, D., Tarai, B., Azie, N., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9090539 · Cited by 90
“auris isolates from a total of 106 isolates were resistant to all tested echinocandins (MIC ≥ 4 μg/mL) and contained an S639F mutation in fks1 [55].”
BackgroundAntifungal Resistance in Candida auris: Molecular Determinants
Frías-De-León, M. G., Hernández-Castro, R., Vite-Garín, T., Arenas, R., Bonifaz, A., Castañón-Olivares, L., Acosta-Altamirano, G., & Martínez-Herrera, E. (2020) · Antibiotics · doi:10.3390/antibiotics9090568 · Cited by 93
Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01419-22 · Cited by 92
Candida auris: Epidemiology and Antifungal Strategy
Eix, E. F., & Nett, J. E. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-061523-021233 · Cited by 74
Keighley, C., Garnham, K., Harch, S. A. J., Robertson, M., Chaw, K., Teng, J. C., & Chen, S. C.-A. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00420-y · Cited by 87
What do we know about the biology of the emerging fungal pathogen of humans Candida auris?
Bravo Ruiz, G., & Lorenz, A. (2021) · Microbiological Research · doi:10.1016/j.micres.2020.126621 · Cited by 85
Candida auris: A Quick Review on Identification, Current Treatments, and Challenges
Černáková, L., Roudbary, M., Brás, S., Tafaj, S., & Rodrigues, C. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094470 · Cited by 92
“Although it was first identified in Japan about a decade ago, presently, several outbreaks have been claimed in several other countries (e.g., Brazil, United States, India, Mexico, Colombia, and in Europe).”
BackgroundMethodInfluentialAhmad, S., Khan, Z., Al‐Sweih, N., Alfouzan, W., & Joseph, L. (2020) · Mycoses · doi:10.1111/myc.13022 · Cited by 79
What Do We Know about Candida auris? State of the Art, Knowledge Gaps, and Future Directions
García-Bustos, V., Cabañero-Navalón, M. D., Ruiz‐Saurí, A., Gaitán, A. C. R., Salavert, M., Tormo‐Más, M. Á., & Pemán, J. (2021) · Microorganisms · doi:10.3390/microorganisms9102177 · Cited by 90
“FKS1 codes the catalytic subunit of the synthase of 1,3-beta-D-glucane—the target of echinocandins—which bestows its resistance [124].”
BackgroundRogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
Burrack, L. S., Todd, R. T., Soisangwan, N., Wiederhold, N. P., & Selmecki, A. (2022) · mBio · doi:10.1128/mbio.00842-22 · Cited by 82
Molecular Epidemiology of Candida Auris Outbreak in a Major Secondary-Care Hospital in Kuwait
Alfouzan, W., Ahmad, S., Dhar, R., Asadzadeh, M., Almerdasi, N., Abdo, N. M., Joseph, L., de Groot, T., Alali, W. Q., Khan, Z., et al. (2020) · Journal of Fungi · doi:10.3390/jof6040307 · Cited by 74
“auris isolates in the presence of caspofungin [33,64].”
BackgroundIn Vitro Antifungal Resistance of Candida auris Isolates from Bloodstream Infections, South Africa
Maphanga, T. G., Naicker, S. D., Kwenda, S., Muñoz, J. F., van Schalkwyk, E., Wadula, J., Nana, T., Ismail, A., Coetzee, J., Govind, C., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00517-21 · Cited by 78
“In addition, S639F/S639P mutations in the FKS1 hot spot 1 region have been detected in echinocandin-resistant isolates (14, 15).”
BackgroundCandida auris: An Overview of How to Screen, Detect, Test and Control This Emerging Pathogen
Fasciana, T., Cortegiani, A., Ippolito, M., Giarratano, A., Diquattro, O., Lipari, D., Graceffa, D., & Giammanco, A. (2020) · Antibiotics · doi:10.3390/antibiotics9110778 · Cited by 84
Saris, K., Meis, J. F., & Voss, A. (2018) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000469 · Cited by 76
Kamli, M. R., Srivastava, V., Hajrah, N. H., Sabir, J. S. M., Hakeem, K. R., Ahmad, A., & Malik, M. A. (2021) · Journal of Fungi · doi:10.3390/jof7010062 · Cited by 76
“auris isolates with mutations in FKS1 gene are considered echinocandin resistant and therefore broth microdilution results for caspofungin results should be treated as reserved [51].”
BackgroundVatanshenassan, M., Boekhout, T., Meis, J. F., Berman, J., Chowdhary, A., Ben-Ami, R., Sparbier, K., & Kostrzewa, M. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00020 · Cited by 66
“Subsequently, the positive blood cultures were purified by MALDI Sepsityper kit (Bruker Daltonik GmbH, Germany) according to the manufacturer’s recommendations (Clark et al., 2013; Lange et al., 2014; Vlek et al., 2014).”
MethodSelf-citationde Oliveira, H. C., Monteiro, M. C., Rossi, S. A., Pemán, J., Ruiz-Gaitán, A., Mendes-Giannini, M. J. S., Mellado, E., & Zaragoza, O. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00083 · Cited by 70
Multidrug-resistant Candida auris : an epidemiological review
Chakrabarti, A., & Singh, S. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1750368 · Cited by 66
“exhibit Eagle effect (also called the paradoxical growth effect) [105].”
BackgroundEmergence of the novel sixth Candida auris Clade VI in Bangladesh
Khan, T., Faysal, N. I., Hossain, M. M., Mah-E-Muneer, S., Haider, A., Moon, S. B., Sen, D., Ahmed, D., Parnell, L. A., Jubair, M., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03540-23 · Cited by 61
Hou, X., Lee, A., Jiménez-Ortigosa, C., Kordalewska, M., Perlin, D. S., & Zhao, Y. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01811-18 · Cited by 66
“In an Indian study, all four isolates containing a serine to phenylalanine amino acid substitution at codon 639 (S639F) had elevated panechinocandin MICs (7) and did not respond to echinocandin therapy in the mouse model of invasive candidiasis (6).”
BackgroundMethodSelf-citationHu, S., Zhu, F., Jiang, W., Wang, Y., Quan, Y., Zhang, G., Gu, F., & Yang, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.658329 · Cited by 64
What’s new on emerging resistant Candida species
Cortegiani, A., Misseri, G., & Chowdhary, A. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5363-x · Cited by 68
Self-citationTools for Detecting a “Superbug”: Updates on Candida auris Testing
Lockhart, S. R., Lyman, M., & Sexton, D. J. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.00808-21 · Cited by 66
“A high number of isolates exhibit the Eagle effect when testing using broth microdilution against caspofungin (13, 55, 56).”
BackgroundAntifungal drug resistance in Candida: a special emphasis on amphotericin B
Ahmady, L., Gothwal, M., Mukkoli, M. M., & Bari, V. K. (2024) · Apmis · doi:10.1111/apm.13389 · Cited by 65
“Moreover, all major Candida species have been linked to acquired echinocandin resistance, but C. glabrata has the highest prevalence [123,124].”
BackgroundSharma, D., Paul, R. A., Rudramurthy, S. M., Kashyap, N., Bhattacharya, S., Soman, R., Shankarnarayan, S. A., Chavan, D., Singh, S., Das, P., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01652-21 · Cited by 60
“(17) demonstrated a poor therapeutic response of S639F FKS1 mutation in C.”
BackgroundMethodInfluentialShivarathri, R., Jenull, S., Stoiber, A., Chauhan, M., Mazumdar, R., Singh, A., Nogueira, F., Kuchler, K., Chowdhary, A., & Chauhan, N. (2020) · mSphere · doi:10.1128/msphere.00973-20 · Cited by 59
Self-citationExpert recommendations for prevention and management of Candida auris transmission
Aldejohann, A. M., Wiese‐Posselt, M., Gastmeier, P., & Kurzai, O. (2022) · Mycoses · doi:10.1111/myc.13445 · Cited by 65
Sharma, C., & Kadosh, D. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011190 · Cited by 63
Abid, F. B., Salah, H., Sundararaju, S., Dalil, L., Abdelwahab, A. H., Salameh, S., Ibrahim, E. B., Almaslmani, M. A., Tang, P., Pérez‐López, A., et al. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.04.025 · Cited by 59
Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox
Kane, A., & Carter, D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040482 · Cited by 59
Prevalence and Therapeutic Challenges of Fungal Drug Resistance: Role for Plants in Drug Discovery
Marquez, L., & Quave, C. L. (2020) · Antibiotics · doi:10.3390/antibiotics9040150 · Cited by 63
Asadzadeh, M., Mokaddas, E., Ahmad, S., Abdullah, A. A., de Groot, T., Meis, J. F., & Shetty, S. A. (2022) · Mycoses · doi:10.1111/myc.13419 · Cited by 55
Antifungal Activity of a Medical-Grade Honey Formulation against Candida auris
de Groot, T., Janssen, T., Faro, D., Cremers, N. A. J., Chowdhary, A., & Meis, J. F. G. M. (2021) · Journal of Fungi · doi:10.3390/jof7010050 · Cited by 58
Self-citationThe global challenge of Candida auris in the intensive care unit
Cortegiani, A., Misseri, G., Giarratano, A., Bassetti, M., & Eyre, D. (2019) · Critical Care · doi:10.1186/s13054-019-2449-y · Cited by 54
The emerging pathogen Candida auris: A focus on the Middle-Eastern countries
Alfouzan, W., Dhar, R., Albarrag, A., & Al-Abdely, H. (2019) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2019.03.009 · Cited by 52
Dickwella Widanage, M. C., Singh, K., Li, J., Yarava, J. R., Scott, F. J., Xu, Y., Gow, N. A. R., Mentink-Vigier, F., Wang, P., Lamoth, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61678-1 · Cited by 51
Zhu, Y., Kilburn, S., Kapoor, M., Chaturvedi, S., Shaw, K. J., & Chaturvedi, V. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01124-20 · Cited by 50
“auris in New York that is exacerbated by the limited availability of effective treatment options (1, 8).”
BackgroundArıkan-Akdağlı, S., Ghannoum, M. A., & Meis, J. F. G. M. (2018) · Journal of Fungi · doi:10.3390/jof4040129 · Cited by 55
Lara-Aguilar, V., Rueda, C., García-Barbazán, I., Varona, S., Monzón, S., Jiménez, P., Cuesta, I., Zaballos, Á., & Zaragoza, Ó. (2021) · Virulence · doi:10.1080/21505594.2021.1927609 · Cited by 40
“To date, Candida resistance to echinocandins is mainly caused by mutations in the FKS genes [57,58].”
BackgroundArastehfar, A. A., Daneshnia, F., Kord, M., Roudbary, M., Zarrinfar, H., Fang, W., Hashemi, S. J., Najafzadeh, M. J., Khodavaisy, S., Pan, W., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00021 · Cited by 52
Dal Mas, C., Rossato, L., Shimizu, T., Oliveira, E. B., da Silva Junior, P. I., Meis, J. F., Colombo, A. L., & Hayashi, M. A. F. (2019) · Biomolecules · doi:10.3390/biom9060205 · Cited by 46
“, azoles, polyenes, and echinocandins [7].”
BackgroundInfluentialGênero Candida - Fatores de virulência, Epidemiologia, Candidíase e Mecanismos de resistência
da Rocha, W. R. V., Nunes, L. E., Neves, M. L. D. R., Ximenes, E. A., & Albuquerque, M. C. P. D. A. (2021) · Research Society and Development · doi:10.33448/rsd-v10i4.14283 · Cited by 76
Kovács, R., Tóth, Z., Locke, J. B., Forgács, L., Kardos, G., Nagy, F., Borman, A. M., & Majoros, L. (2021) · Microorganisms · doi:10.3390/microorganisms9040863 · Cited by 46
Marena, G. D., Ramos, M. A. D. S., de Lima, L. C., Chorilli, M., & Bauab, T. M. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.151023 · Cited by 43
Emerging and future strategies in the management of recalcitrant Candida auris
Bandara, N., & Samaranayake, L. P. (2022) · Medical Mycology · doi:10.1093/mmy/myac008 · Cited by 51
Iyer, K. R., Whitesell, L. J., Porco, J. A. J., Henkel, T. O., Brown, L. E., Robbins, N., & Cowen, L. E. (2020) · mBio · doi:10.1128/mbio.03329-19 · Cited by 48
Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health
de Oliveira, H. C., Bezerra, B. T., & Rodrigues, M. L. (2022) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00055 · Cited by 46
Fayed, B., Jayakumar, M. N., & Soliman, S. S. M. (2021) · Medical Mycology · doi:10.1093/mmy/myab059 · Cited by 41
da Silva, T. A., Hauser, P. J., Bandey, I. N., Laskowski, T. J., Wang, Q., Najjar, A. M., & Kumaresan, P. R. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.11.002 · Cited by 42
Plant-Derived Substances in the Fight Against Infections Caused by Candida Species
Guevara-Lora, I., Braś, G., Karkowska‐Kuleta, J., Gonzalez‐Gonzalez, M., Ceballos, K., Sidlo, W., & Rąpała‐Kozik, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176131 · Cited by 44
Overview about Candida auris: What's up 12 years after its first description?
Désoubeaux, G., Coste, A. T., Imbert, C., & Hennequin, C. (2022) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2022.101248 · Cited by 43
Al-Obaid, I., Asadzadeh, M., Ahmad, S., Alobaid, K., Alfouzan, W., Bafna, R., Emara, M., & Joseph, L. (2022) · Journal of Fungi · doi:10.3390/jof8030267 · Cited by 39
Florio, W., Tavanti, A., Ghelardi, E., & Lupetti, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02577 · Cited by 43
“, 2014), the emerging pathogen Candida auris (Bao et al., 2018; Kohlenberg et al., 2018; Kordalewska et al., 2018), Trichosporon spp.”
BackgroundApplication of Machine Learning Classifier to Candida auris Drug Resistance Analysis
Li, D., Wang, Y., Hu, W., Chen, F., Zhao, J., Chen, X., & Li, H. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.742062 · Cited by 40
Govender, N. P., Avenant, T., Brink, A. J., Chibabhai, V., Cleghorn, J., du Toit, B., Govind, C., Lewis, E., Lowman, W., Mahlangu, H., et al. (2019) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v34i1.163 · Cited by 46
Pfaller, M. A., Messer, S. A., Deshpande, L. M., Rhomberg, P. R., Utt, E. A., & Castanheira, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02031-20 · Cited by 37
“auris isolates is mediated through limited mutations in FKS1, usually encoding S639P or S639F (12).”
BackgroundInfluentialCandida Pathogenicity and Interplay with the Immune System
Valand, N., & Girija, U. V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-67452-6_11 · Cited by 41
Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients
Downes, K. J., Fisher, B. T., & Zane, N. R. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00379-2 · Cited by 37
Stavrou, A. A., Hansen, A. P., Lackner, M., Lass‐Flörl, C., & Boekhout, T. (2020) · Medical Mycology · doi:10.1093/mmy/myaa005 · Cited by 38
Chitosan Ameliorates Candida auris Virulence in a Galleria mellonella Infection Model
Arias, L. S., Butcher, M. C., Short, B., McKloud, E., Delaney, C., Kean, R., Monteiro, D. R., Williams, C., Ramage, G., & Brown, J. L. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-20 · Cited by 39
“a mutation FKS1 gene, which encodes for a 1-3- -glucan synthase enzyme (34).”
BackgroundHow urgent is the need for new antifungals?
Stewart, A. G., & Paterson, D. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1935868 · Cited by 36
Siopi, M., Pachoulis, I., Leventaki, S., Spruijtenburg, B., Meis, J. F. G. M., Pournaras, S., Vrioni, G., Tsakris, A., & Meletiadis, J. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01528-23 · Cited by 34
“Specifically for C. auris , BMD susceptibility testing to caspofungin has been discouraged since caspofungin induces significant Eagle effect resulting in an overestimation of the resistant population, while only FKS mutant isolates are truly echinocandin-resistant (35).”
BackgroundMolecular Diagnostics in the Times of Surveillance for Candida auris
Kordalewska, M., & Perlin, D. S. (2019) · Journal of Fungi · doi:10.3390/jof5030077 · Cited by 38
“auris isolates to the echinocandin treatment as was shown in an invasive murine candidiasis model [17].”
BackgroundMethodSelf-citationTan, Y. E., Teo, J. Q.-M., Rahman, N. B. A., Ng, O. T., Marimuthu, K., Tan, A. L., Koh, T. H., & Ong, R. T. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.09.016 · Cited by 37
Ibrexafungerp: A narrative overview
Ayoubi, L. W. E., Allaw, F., Moussa, E., & Kanj, S. S. (2024) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2024.100245 · Cited by 41
“The widespread use of echinocandins has resulted in resistance in several Candida spp., particularly in isolates of Nakaseomyces glabrata (formerly C. glabrata) and C. auris (Alexander et al., 2013; Kordalewska et al., 2018; Naicker et al., 2016).”
BackgroundJenull, S., Shivarathri, R., Tsymala, I., Penninger, P., Trinh, P.-C., Nogueira, F., Chauhan, M., Singh, A., Petryshyn, A., Stoiber, A., et al. (2022) · mBio · doi:10.1128/mbio.00799-22 · Cited by 32
“2 mg/mL for CSP [37]), these isolates can be considered ECN-R, as pointed out previously (36).”
BackgroundResultSelf-citationTranscriptome Signatures Predict Phenotypic Variations of Candida auris
Jenull, S., Tscherner, M., Kashko, N., Shivarathri, R., Stoiber, A., Chauhan, M., Petryshyn, A., Chauhan, N., & Kuchler, K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.662563 · Cited by 32
Kiyohara, M., Miyazaki, T., Okamoto, M., Hirayama, T., Makimura, K., Chibana, H., Nakada, N., Ito, Y., Sumiyoshi, M., Ashizawa, N., et al. (2023) · Journal of Fungi · doi:10.3390/jof9050529 · Cited by 32
Pezzotti, G., Kobara, M., Asai, T., Nakaya, T., Miyamoto, N., Adachi, T., Yamamoto, T., Kanamura, N., Ohgitani, E., Marin, E., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.769597 · Cited by 33
“Alterations in the ergosterol pathway, which in turn depend on ergosterol gene mutations, are considered the main responsible for resistance to amphotericin B (Kordalewska et al., 2018).”
Backgroundda Silva Dantas, A., Nogueira, F., Lee, K. K., Walker, L. A., Edmondson, M., Brand, A. C., Lenardon, M. D., & Gow, N. A. R. (2021) · Journal of Cell Science · doi:10.1242/jcs.258889 · Cited by 31
Novel Non-Hot Spot Modification in Fks1 of Candida auris Confers Echinocandin Resistance
Kordalewska, M., Cancino-Prado, G., de Almeida, J. N., Brandão, I. B., Peral, R. T. D. S., Colombo, A. L., & Perlin, D. S. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00423-23 · Cited by 33
Self-citationEvolutionary accumulation of FKS 1 mutations from clinical echinocandin-resistant Candida auris
Tian, S., Wu, Y., Li, H., Chen, R., Wu, N., Chu, Y., Jiang, N., Zhang, J., & Shang, H. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2377584 · Cited by 34
“Research on the mechanism of echinocandin resistance in C. auris has primarily focused on mutations in the FKS 1 gene [8,9] (mainly FKS 1 S639Y , FKS 1 S639F , and FKS 1 S639P ), but few studies have assessed the drivers of these FKS 1 mutations [10].”
Uniqueness of Candida auris cell wall in morphogenesis, virulence, resistance, and immune evasion
Dakalbab, S., Hamdy, R., Holigová, P., Abuzaid, E. J., Abu-Qiyas, A., Lashine, Y., Mohammad, M. G., & Soliman, S. S. M. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127797 · Cited by 31
Hsu, C., & Yassin, M. (2025) · Microorganisms · doi:10.3390/microorganisms13071461 · Cited by 34
“This phenomenon may result in inconsistent MIC readings and misclassification of susceptible isolates as resistant, particularly if additional echinocandins are not tested alongside caspofungin [123].”
Metadata
- Authors
- Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S.
- Affiliations
- Rutgers Health (US)
- Medical and Experimental Mycology Group, Corporación para Investigaciones Biológicas (CIB), Medellín, Colombia
- University of Delhi (IN)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-06
- Volume
- 62
- Issue
- 6
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5971591
- OpenAlex
- W2795884050
- Cited by
- 247
- References
- 47
- Citations by year
- 2026: 29 · 2025: 24 · 2024: 22 · 2023: 29 · 2022: 29 · 2021: 43 · 2020: 36 · 2019: 24 · 2018: 10
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (AI109025)
- Astellas Pharma US
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- Candida auris, echinocandin resistance, FKS1 mutations, caspofungin, micafungin, antifungal susceptibility testing, invasive candidiasis, mouse model, nosocomial fungal infections
- MeSH terms
- Animals, Antifungal Agents, Candida, Candidiasis, Cross Infection, Female, Glucosyltransferases, Humans, Mice, Inbred BALB C, Microbial Sensitivity Tests, Drug Resistance, Fungal, Mice, Echinocandins, Candidiasis, Invasive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.